Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.18
$0.01(1.52%)
At close: 4:00 PM EST
$0.18
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$1.17 - $16.39
Previous CloseN/A
Volume29.92K
Average Volume (3M)19.46M
Market Cap
$12.10M
Enterprise Value$16.35M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$11.42M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 19, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.25
Shares Outstanding8,960,523
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue6.63
Enterprise Value/Gross Profit7.39
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$16.00Price Target Upside8788.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.33
Revenue Forecast (FY)$2.45M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthSustained triple-digit YoY top-line growth shows early commercial traction for Nu.Q® products and expanding sales capacity. Over 2–6 months this trend supports stronger partner engagement and scale economies if management converts technical wins into repeatable revenue streams.
Strong Early-Detection Science (Capture-Seq)High sensitivity and claimed >99% ctDNA purity create durable scientific differentiation and IP leverage. Peer-reviewed manuscripts, patents and strong early validation bolster long-term clinical adoption potential and partner interest, supporting future commercialization and reimbursement discussions.
Productization & Commercial Milestones (Nu.Q Vet)Achieving lab automation with Fujifilm and a potential $5M milestone evidences product readiness and scalable lab deployment. Automation enables recurring reagent/test sales and partner-led rollouts, making the vet channel a durable revenue pathway beyond one-off research income.
Bears Say
Severe Cash Burn And Negative EquityLarge negative operating and free cash flows and sustained negative equity materially limit self-funding capacity. Over months this forces continued external financing, constrains R&D/commercial investments, and increases the probability of dilutive capital or curtailed programs if milestones slip.
Reliance On Financing And Covenant WaiversFrequent private financings and a waived market-cap covenant with penalty expose the company to lender control and conversion dilution risk. Structurally, this reduces strategic flexibility, elevates refinancing risk, and can divert management focus to covenant compliance rather than scaling core operations.
Lumpy Revenue And No Near-Term GuidanceUnpredictable, milestone-driven sales and deferred recognition make cash flow forecasting difficult. Over a 2–6 month horizon this impairs planning for commercialization, hiring, and capex, and heightens dependence on milestone/grant timing rather than stable recurring revenue growth.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $1.17 and its highest was $16.39 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $12.10M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 19, 2026 which is in 49 days.
How were VolitionRX’s earnings last quarter?
Currently, no data Available
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.61.
How many shares outstanding does VolitionRX have?
VolitionRX has 8,960,523 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VNRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial scientific and commercial progress across multiple product pillars (Nu.Q Vet automation and feline assay, Nu.Q NETs publications and point-of-care finger-prick breakthrough, Capture-Seq >99% pure ctDNA claims, Nu.Q Discover expansion), alongside improving headline revenue (+300% YoY) and a stronger quarter-end cash balance driven by financing and grants. However, important caveats include revenue lumpiness driven in part by deferred recognition, rising operating expenses and cash burn, reliance on milestone payments and external financing, and the need for broader validation, publications, and regulatory/reimbursement approvals to convert technical advances into predictable commercial revenue. On balance, the call signals strong technical momentum and growing commercial interest but with execution and timing risks to monetize those advances in the near term.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(8788.89% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.15% Mutual Funds
― Other Institutional Investors
88.47% Public Companies and
Individual Investors